The renin angiotensin system and cardiovascular disease: hope or hype?

Lee MA , Bohm M. , Paul M. , Ganten D. Tissue renin angiotensin systems and their role in cardiovascular diseases . Circulation 1993; 87: 7-13.

Berk BC , Vekshtein V. , Gordon HM , Tsuda T. Angiotensin II stimulated protein synthesis in cultured vascular smooth muscle cells. Hypertension 1989;13:305-14.

NaftilanAJ, Gilliland GK , Eldridge CS , KraftAS. Induction of the proto-oncogene c-jun by angiotensin II. Mol Cell Biol 1990; 10:5536-40.

Kranzhofer R. , Schmidt J. , Pfeiffer CA , Hagl S. , Libby P. , Kubler W. Angiotensin induces inflammatory activation of human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 1999; 19:1623-9.

Himeno H. , Crawford DC , Hosoi M. , Chobanian AV , Brecher P. Angiotensin II alters aortic fibronectin independently of hypertension . Hypertension 1991; 23: 823-6.

Griendling K. , Ollerenshaw JD , Minieri CA , Alexander RW Angiotensin II stimulates NADH and NADPH activity in cultured vascular smooth muscle cells . Circ Res 1994; 74: 1141-8.

Rajagopaian S. , Kurz S. , Munzel T. et al. Angiotensin II mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. J Clin Invest 1996; 97:1916-23.

Warnholtz A. , Nickenig G. , Schultz E. et al. Increased NADHoxidase-mediated superoxide production in the early stages of atherosclerosis; evidence for involvement of the reninangiotensin system. Circulation 1999; 99:2027-33.

Strawn WB , Chappell MC , Dean RH , Kivlighn S. , Ferrario CM Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolaemia. Circulation 2000; 101:1586-93.

Williams B. Angiotensin II,VEGF and diabetic retinopathy. Lancet 1998; 351: 837-8.

Birkenboom G. Unstable atherosclerotic plaque. Pathophysiology and therapeutic implications. Acta Cardiol 1998,53:235-41.

The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS) . N Engl J Med 1987; 316:1429-35.

Pfeffer MA , Braunwald E. , Moye LA et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992; 27:669-77.

Williams B. The renin angiotensin system in the pathogenesis of diabetic complications . In: Mogensen CE (ed.) The kidney and hypertension in diabetes. Kluwer Academic publications 2000: 645-54.

Cooper ME Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet 1998;352:213-9.

Chaturvedi N. , Sjolie A. -K, Stephenson JM et al. Effects of lisinopril on progression of retinopathy in normotensive people with type I diabetes . Lancet 1998; 351: 28-31.

Hansson L. , Lindholm LH , Niskanen L. et al. Effect of angiotensin-converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP). Lancet 1999; 353:611-615.

Hansson L. , Lindholm LH , Ekbom T. et al. Randomised trial of old and new hypertensive drugs in elderly patients: cardiovascular morbidity and mortality in the Swedish Trial of Old Patients with hypertension-2 study. Lancet 1999; 354:1751-6.

The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high risk patients . N Eng J Med 2000; 342:145-53.

The Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355:253-9.

Williams B. Diabetes is a vascular disease. Acta Diabetol 1999; 36: 1-3.

Clarke R. , Shipley M. , Lewington S. et al. Underestimation of risk associations due to regression dilution in long term follow-up of prospective studies. Am J Epidemiol 1999; 150:341-53.

Kannel WB Potency of vascular risk factors as the basis for antihypertensive therapy . Eur Heart J 1992;13(suppl G):34-42.

Williams B. The unique vulnerability of diabetic subjects to hypertensive injury. J Human Hypertension 1999;13:3-8.

Williams B. Treating hypertension in type 2 diabetes: An evidence base at last. Acta Diabetol 1999;36:4-10.

Hansson L. , Zanchetti A. , Carruthers SG et al for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998;351:1755-62.

Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure and the National High Blood Pressure Education Program Coordinating Committee. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med;157:2413-46.

Ramsay LE , Williams B. , Johnston DG et al. British Hypertension Society guidelines for hypertension management 1999:A summary. BMJ 1999;319:630-5.

Tuomilehto J. , Rastenyte D. , Birkenhager WH et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Syst Eur Investigators . N Eng J Med 1999;340:677-84.

United Kingdom prospective diabetes study group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. UKPDS 38. BMJ 1998;317:703-13.